Evidence map›Paper›PMID 41629737›Full record

ArticleEndocrine2026

Sex differences in cardiovascular risk factors and cardiovascular disease in patients with hyperprolactinemia: a multicenter cross-sectional study.

Pedro Iglesias, María Dolores Moure Rodríguez, Fernando Guerrero-Pérez, Andreu Simó Servat, Laura González Fernández, Eva Fernández-Rodríguez, Patricia Pérez Castro, Rocío Villar-Taibo, Betina Biagetti, Aida Orois and 15 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Pedro IglesiasEndocrinology & Nutrition Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain. piglo65@gmail.com.
María Dolores Moure RodríguezEndocrinology & Nutrition Department, Hospital Universitario Cruces, Bilbao, Spain.
Fernando Guerrero-PérezEndocrinology & Nutrition Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
Andreu Simó ServatEndocrinology & Nutrition Department, Hospital Universitari MutuaTerrassa and Terrassa Health Consortium, Terrassa, Spain.
Laura González FernándezEndocrinology & Nutrition Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Eva Fernández-RodríguezEndocrinology & Nutrition Department, Complexo Hospitalario Universitario de Ourense, Ourense, Spain.
Patricia Pérez CastroEndocrinology & Nutrition Department, Complejo Hospitalario Universitario de Vigo, Vigo, Spain.
Rocío Villar-TaiboEndocrinology & Nutrition Department, Hospital Universitario de Santiago, Santiago de Compostela, Spain.
Betina BiagettiEndocrinology & Nutrition Department, Hospital Universitario Vall de Hebrón, CIBERER U747 (ISCIII), ENDO-ERN, Universitat Autónoma de Barcelona, Barcelona, Spain.
Aida OroisEndocrinology & Nutrition Department, Hospital Clínic de Barcelona, Barcelona, Spain.
Sara DonatoEndocrinology & Nutrition Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Victoria Alcázar LázaroEndocrinology & Nutrition Department, Hospital Universitario Severo Ochoa, Madrid, Spain.
Noel Roig-MarínEndocrinology & Nutrition Department, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.
Guillermo SerraEndocrinology & Nutrition Department, Hospital Universitario Son Espases, Palma de Mallorca, Spain.
Soralla CivantosEndocrinology & Nutrition Department, Hospital Universitario de Fuenlabrada, Madrid, Spain.
Gonzalo RiveroEndocrinology & Nutrition Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
Carmen María Fernandez de AraozEndocrinology & Nutrition Department, Hospital Universitario de Getafe, Madrid, Spain.
Isabel Pavón de PazEndocrinology & Nutrition Department, Hospital Universitario de Getafe, Madrid, Spain.
Fernando CordidoEndocrinology & Nutrition Department, Hospital Universitario A Coruña, A Coruña, Spain.
Rogelio García CentenoEndocrinology & Nutrition Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Marta Araujo-CastroEndocrinology & Nutrition Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Cristina LamasEndocrinology & Nutrition Department, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.
Miguel PajaEndocrinology & Nutrition Department, OSI Bilbao-Basurto. Hospital Universitario de Basurto, Bilbao, Spain.
Felicia Alexandra HanzuEndocrinology & Nutrition Department, Hospital Clinic, University of Barcelona, IDIPAS , Barcelona, Spain.
Juan J DíezEndocrinology & Nutrition Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHyperprolactinemia is classically linked to reproductive dysfunction, but emerging evidence suggests an association with metabolic and cardiovascular (CV) risk. This study evaluated sex differences in CV risk factors (CVRFs) and cardiovascular disease (CVD) in patients with hyperprolactinemia.

methodsA multicenter, retrospective cross-sectional study was conducted in 449 adult patients (199 men, 250 women) with confirmed hyperprolactinemia from 19 tertiary referral centers in Spain. Clinical, biochemical, and hormonal data were collected and analyzed. The prevalence of CVRFs and CVD was compared between sexes. Associations between serum prolactin levels and CVRFs/CVD were assessed using nonparametric tests, correlation analyses, and multivariable logistic regression.

resultsMen had significantly higher serum prolactin levels than women (median 796 [IQR 250–1499] vs. 114 [74.5–224] ng/mL; p < 0.001) and a greater crude prevalence of all major CVRFs (p < 0.001 for all). After adjustment for age, male sex remained independently associated with smoking (OR 2.16; p = 0.007) and hyperlipidemia (OR 1.97; p = 0.031). Serum prolactin levels positively correlated with age, BMI, systolic blood pressure, glucose, total cholesterol, and triglycerides (all p < 0.001). In sex-stratified analyses, prolactin was associated with BMI and lipid profile in men, and with hypertension and hyperlipidemia in women. Prolactin levels were significantly elevated in patients with any form of CVD (p = 0.007), particularly arrhythmias (p = 0.013), while a trend was noted for ischemic heart disease (p = 0.050).

conclusionMen with hyperprolactinemia exhibit a more adverse cardiometabolic profile, characterized by higher serum prolactin levels and a greater burden of classical CVRFs and CVD. Prolactin concentrations are positively associated with multiple metabolic and CV parameters, with sex-specific patterns suggesting distinct mechanisms of susceptibility and regulation. These findings underscore the importance of incorporating sex and hormonal context into CV risk assessment in patients with hyperprolactinemia.

Indexed as

Cardiovascular DiseasesHeart Disease Risk FactorsHyperprolactinemiaAdultAgedCross-Sectional StudiesFemaleHumansMaleMiddle AgedPrevalenceProlactinRetrospective StudiesRisk FactorsSex CharacteristicsSex FactorsProlactinCardiovascular RiskDyslipidemiaHyperprolactinemiaMetabolic SyndromeProlactinSex Differences

Identifiers

PMID41629737

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.